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Abstract
Background Colorectal cancer develops in a multi-step man-
ner from normal epithelium, through a pre-malignant lesion
(so-called adenoma), into a malignant lesion (carcinoma),
which invades surrounding tissues and eventually can spread
systemically(metastasis).Itis estimatedthatonlyabout 5%of
adenomas do progress to a carcinoma.
Aim The present study aimed to unravel the biology of
adenoma to carcinoma progression by mRNA expression
profiling, and to identify candidate biomarkers for adenomas
that are truly at high risk of progression.
Methods Genome-wide mRNA expression profiles were
obtained from a series of 37 colorectal adenomas and 31
colorectal carcinomas using oligonucleotide microarrays.
Differentially expressed genes were validated in an indepen-
dent colorectal gene expression data set. Gene Set Enrich-
ment Analysis (GSEA) was used to identify altered
expression of sets of genes associated with specific biolog-
ical processes, in order to better understand the biology of
colorectal adenoma to carcinoma progression.
Results mRNA expression of 248 genes was significantly
different, of which 96 were upregulated and 152 downregu-
lated in carcinomas compared to adenomas. Classification
of adenomas and carcinomas using the expression of these
genes showed to be very accurate, also when tested in an
independent expression data set. Gene-sets associated with
ageing (which is related to senescence) and chromosomal
instability were upregulated, and a gene-set associated with
fatty acid metabolism was downregulated in carcinomas
compared to adenomas. Moreover, gene-sets associated with
chromosomal location revealed chromosome 4q22 loss and
chromosome 20q gain of gene-set expression as being rele-
vant in this progression.
Concluding remark These data are consistent with the no-
tion that adenomas and carcinomas are distinct biological
entities. Disruption of specific biological processes like
senescence (ageing), maintenance of chromosomal instability
and altered metabolism, are key factors in the progression
from adenoma to carcinoma.
Keywords Colorectalcancer.Progression.Gene
expression.Ageing.Chromosomalinstability.Fattyacid
metabolism
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Colorectal cancer (CRC) is a major health concern world-
wide. In Europe, CRC ranks second in terms of cancer
incidence and mortality, after lung cancer [1]. Most often
the disease is only diagnosed at a late stage, when clinical
symptoms arise.
CRC develops in a multi-step manner from normal epithe-
lium, through a pre-malignant lesion (so-called adenoma),
into a malignant lesion (carcinoma), which invades surround-
ing tissues and eventually can spread systemically (metasta-
sis). While pre-malignant lesions, adenomas, can easily be
detected by colonoscopy, most of these adenomas have a
low risk of progressing into cancer. It is estimated that this
happens in about 5% of adenomas [2, 3]. Unravelling the
biology of adenoma to carcinoma progression is crucial for
identifying biomarkersfor adenomas that are truly athigh risk
of progression.
By genome-wide analysis of DNA copy number changes
we have shown that adenomas harbouring a focus of carcino-
ma (progressed adenomas), already contain in their phenotyp-
ically still benign components most chromosomal aberrations
that are present in their invasive counterpart [4, 5]. This
indicates that these chromosomal regions harbour genes that
play a role in the adenoma-to-carcinoma progression.
Many genes have been implicated in the development of
CRC. Initially, APC, KRAS, TP53 and DCC have been
described in the progression model introduced by Fearon
and Vogelstein [6]. More recently, by sequencing a panel of
11 colorectal cancers, Wood et al [7] identified 140 candi-
date cancer genes (CAN genes) mutated in CRC. As gene
expression can be affected in multiple ways, including DNA
copy number dosage and epigenetic silencing, studies inte-
grating both copy number changes and point mutations [8,
9] as well as mutations and hypermethylation of promoter
regions of genes [10] have enabled the discovery of addi-
tional genes and pathways relevant to CRC development.
One example of a clinically relevant gene involved in CRC
progression is AURKA, which is both amplified and over-
expressed in the majority of CRCs [5, 11, 12] and is a target
for anti-cancer drugs [13].
Microarray expression profiling is a robust technique to
analyse the expression of thousands of genes simultaneous-
ly. Gene expression in CRC has been widely studied with
microarrays, either comparing carcinomas to normal colon
tissue [14–18] or by comparing microsatellite instable with
microsatellite stable CRCs [19, 20]. In addition, the mech-
anisms of metastasis [21–25], prediction of recurrence risk
of stage II and stage III CRCs [26–29] and response to
treatment in advanced CRC patients [30] have been inves-
tigated using expression profiling. To date, a limited number
of studies have focused on the differential expression be-
tween colorectal adenomas and carcinomas and in most of
them the number of samples analysed was rather limited,
especially concerning the number of adenomas [31–34].
After having studied differential mRNA expression of
designated cancer pathways between colorectal adenomas
and carcinomas [35], we set out to identify in an unbiased
approach which genes show altered expression during pro-
gression from adenoma to carcinoma, using the same data
set of 37 colorectal adenomas and 31 colorectal carcinomas
analysed by oligonucleotide microarrays.
Gene Set Enrichment Analysis (GSEA) was used to
identify altered expression of sets of genes associated with
specific biological processes in order to identify the molec-
ular mechanisms that drive colorectal adenoma to carcinoma
progression.
2 Material and methods
2.1 Samples data set
Expression microarray data available from 68 snap-frozen
colorectal tumour samples (37 adenomas and 31 carcino-
mas) prospectively collected at the VU University medical
center (VUmc), Amsterdam, the Netherlands [5] were ana-
lysed in the present study. The study was carried out in
accordance with the ethical guidelines of our institution
concerning informed consent about the use of patient’s
material after endoscopic or surgical procedures. The 68
frozen specimens corresponded to 31 females and 34 males
(3 patients had multiple tumours). The mean age was 69
(range 47–89). Supplementary Table 1 shows all relevant
clinical information about the samples used. Evaluation
of tumour content was done by a pathologist (G.A.M.)
on 4 μm haematoxylin and eosin-stained cryo sections
obtained before and after (i.e. sandwich method) the
tissue part from which RNA was isolated. Only cases
containing at least 70% of tumour cells in both 4 μm
sections were considered for further analysis [5]. All
expression microarray data are available at Gene Expres-
sion Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/
[36], accession number GSE8067.
2.2 Microarray data analysis
As all hybridisations were performed dual channel using a
common reference, all comparisons were relative between
colorectal adenomas and carcinomas.
Supervisedanalysisforcomparingcarcinomastoadenomas
was done using the Wilcoxon signed rank test. Genes were
considered to be differentially expressed in a genome-wide
setting when the p-value was less than 1e-5 (False discovery
rate; FDR<0.1).
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PAM [37] was used to classify our samples based on the
gene expression signatures. Leave One Out Cross Validation
(LOOCV) was used to evaluate the classification accuracy
of the entire data set. The cross validation process was run
100 times. This strategy was also applied on an independent
micoarray expression data set (GEO database accession
number GSE20916) [34] containing 45 adenomas and 36
carcinomas.
2.4 Gene Set Enrichment Analysis (GSEA)
Association of the differential expression with biological
processes was performed using Gene Set Enrichment Anal-
ysis (GSEA v2.0, http://www.broad.mit.edu/gsea/)[ 38].
GSEA makes use of the fact that changes in biological
characteristics require coordinate variation in expression of
groups of genes, i.e. gene-sets, which regulate biological
activity. While absolute changes in expression levels of the
majority of individual genes are often modest to small and
do not reach statistical significance, GSEA allows to esti-
mate group-wise variation in expression of pre-defined
gene-sets, indicative for pathway activity levels. In brief,
GSEA performs a competitive analysis of pre-defined gene-
sets, whereby all genes analysed by expression arrays are
ranked according to their differential expression between
two sample groups (i.e. colorectal adenomas and carcino-
mas). GSEA calculates a pathway Enrichment Score (ES)
that estimates whether genes from pre-defined gene-sets are
enriched among the highest- (or lowest-) ranked genes or
whether they are distributed randomly. Default settings were
used. Thresholds for significance were determined by permu-
tation analysis (1000 permutations). False Discovery Rate
(FDR), i.e.correction for multiple testing, q-values < 0.1 were
considered significant.
For GSEA analysis, a total of 3,732 pre-defined gene-sets
were available. We analysed the data using three different
types of gene-sets, namely ontology gene-sets (n01454; of
which 1,057 were selected using the default setting -
microarray results for at least 15 genes per gene-set), curated
gene-sets (n01892; of which 1,434 were selected using the
default setting) and gene-sets organized by chromosomal
position (n0386; of which 257 were selected using the
default setting).
2.5 Identification of key genes for pathway activity
Individual genes from cancer-related gene-sets for which
mRNA expression levels differed most between colorectal
adenomas and CRCs, were considered key genes for path-
way activity. For individual genes within cancer related
gene-sets that contributed to the enrichment score,
Wilcoxon-ranking test p-values < 1e-5, which in our setting
implied FDR < 0.1, of the differential expression at the
single gene level were considered significant.
Table 1 Top 20 significantly upregulated and downregulated genes in
colorectal carcinomas in comparison with adenomas
Gene Symbol Refseq P-value
Wilcoxon test
Upregulated
SPON2 NM_012445 2.46E-10
RGS16 NM_002928 8.02E-10
LY6E NM_002346 3.16E-09
SFRP4 NM_003014 8.27E-09
MFAP2 NM_017459 9.57E-09
AURKA NM_003600 1.28E-08
LOC283658 AL833463 2.11E-08
TIE1 NM_005424 2.27E-08
CTHRC1 NM_138455 6.03E-08
BMP7 AK094784 6.46E-08
C20ORF20 NM_018270 9.72E-08
– AL548449 1.56E-07
ISG15 NM_005101 1.56E-07
SLC27A5 NM_012254 1.56E-07
SSSCA1 NM_006396 1.56E-07
TROAP NM_005480 1.66E-07
CCL21 NM_002989 1.78E-07
TCFL5 NM_006602 1.78E-07
CENPH NM_022909 1.90E-07
PLSCR3 NM_020360 2.03E-07
Downregulated
FAM55D NM_152315 1.48E-09
PRKACB NM_002731 1.87E-09
CLIC3 NM_004669 2.17E-09
ENTPD5 NM_001249 2.72E-09
ATOH8 NM_032827 3.67E-09
SLITRK6 NM_032229 4.59E-09
PTGER4 NM_000958 4.59E-09
CACNA2D2 NM_006030 5.32E-09
TBX3 NM_016569 6.17E-09
RETNLB NM_032579 6.64E-09
GLYATL1 NM_080661 6.64E-09
– AW975332 8.90E-09
ID4 NM_001546 1.19E-08
– AK095147 1.28E-08
UGT1A6 NM_001072 1.28E-08
LOC645904 BM545871 1.70E-08
VSIG2 NM_014312 2.27E-08
– BC039491 2.43E-08
KLHL18 BC015962 2.61E-08
– AK026378 2.80E-08
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Microarray expression analysis was performed on snap-
frozen samples from 37 adenomas and 31 carcinomas.
Expression of 248 genes were significantly different
between adenomas and carcinomas (Wilcoxon rank test,
p<1e-5), after the analysis of the whole data set (28830
probes). Of these, 96 were significantly upregulated in
carcinomascomparedtoadenomasand152weresignificantly
downregulated in carcinomas compared to adenomas. The top
20ofbothupregulated anddownregulatedgenes are shownin
Table 1. A complete list of the differentially expressed genes,
upregulated and downregulated in carcinomas is presented in
Supplementary Tables 2 and 3, respectively. The most upre-
gulated genes in carcinomas in comparison to adenomas were
Spondin 2 (SPON2) and Regulator of G-Protein signalling 16
(RGS16), located at chromosome arms 4p16.3 and at 1q25.3,
respectively. The most downregulated genes in carcinomas in
comparisontoadenomaswerefamilywithsequencesimilarity
55, member D (FAM55D) and protein kinase, cAMP-
dependent, catalytic, beta (PRKACB), located at chromosome
arms 11q23.1 and 1p36.1, respectively.
PAM analysis using LOOCV to accurately classify the
tumours as adenomas or carcinomas, on the whole gene data
set, revealed a set of eight genes that were frequently selected
in the 100 runs (Table 2). All eight genes were included in the
248 differentially expressed genes, namely the top upregu-
lated (SPON2) and the top downregulated (FAM55D) genes.
Next, we wanted to check if the expression of the differ-
entially expressed genes (n0248 genes) would be accurate
enough to classify adenomas and carcinomas in an indepen-
dent adenomas and carcinomas expression dataset. We used
the expression dataset of Skrzypczak and collaborators [34],
from which we were able to match 169 genes out of 248.
From this analysis, we observed that this set of genes was
able to classify adenomas and carcinomas with 71% accu-
racy (Table 3). The same analysis using only the set of
upregulated genes (n096) was performed, as these are suit-
able candidates to be used as biomarkers in clinical practice.
From this analysis, we observed that this set of upregulated
genes, from which we were able to match 71 genes out of
96, was able to classify adenomas and carcinomas with 89%
accuracy (Table 4).
To compare mRNA expression between colorectal ade-
nomas and carcinomas at the pathway level, we performed
gene set enrichment analysis (GSEA). Data were analysed
usingthreedifferenttypesofgene-sets;i.e.ontologygene-sets
(gene-setsorganisedbybiologicalprocess,molecularfunction
and cellular component), curated gene-sets (gene-sets collect-
ed from various sources such as online pathway databases,
publications in PubMed, and knowledge of domain experts)
and gene-sets organised by chromosomal position (gene-sets
corresponding to each human chromosome and each cytoge-
netic band that has at least one gene).
Within these biological processes, pathways or locations,
those genes whose expression was also significantly differ-
ent between adenomas and carcinomas at an individual level
were considered as biomarkers or key genes reflecting the
changes occurring within these pathways during progression
from adenoma to carcinoma.
Of the 1,057 ontology gene-sets analysed, twenty one
were significantly differentially expressed between adeno-
mas and carcinomas (FDR < 0.1) (Table 5) These were all
upregulated in carcinomas compared to adenomas and most
were involved in chromosome binding, chromosome segre-
gation, mitosis or cell cycle. Key genes recurrently observed
within these pathways are Structural maintenance of chro-
mosomes 1A (SMC1A), Aurora kinase A (AURKA), TPX2,
Table 2 Frequently selected features (in 100 runs) with Leave One
Out Cross Validation (LOOCV) applied to the whole data set
Accession number Gene Symbol Nr. of times selected
AK095147 FLJ37828 100
BM545871 LOC645904 100
NM 004669 CLIC3 100
NM 012445 SPON2 2
NM 032229 SLITRK6 100
NM 032579 RETNLB 100
NM 080661 GLYATL1 100
NM 152315 FAM55D 100
Table 3 Average classification percentage (100 runs) of the 169
matched genes (out of 248 differentially expressed genes) on the
independent expression data set from Skrzypczak et al. [34] containing
45 adenomas and 36 carcinomas
Predicted
a Total
Adenoma Carcinoma
True Adenoma 45 0 45
Carcinoma 23.41 12.59 36
aOverall misclassification 28.90
Table 4 Average classification percentage (100 runs) of the 71
matched genes (out of 96 upregulated genes) on the independent
expression data set from Skrzypczak et al. [34] containing 45 adenomas
and 36 carcinomas
Predicted
a Total
Adenoma Carcinoma
True Adenoma 37.14 7.86 45
Carcinoma 1 35 36
a Overall misclassification 10.94
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adenoma to carcinoma progression (FDR < 0.10)
a
Gene set
(FDR value)
Carcinoma
vs adenoma
Gene
Symbol
P-value
(Wilcoxon
signed
rank test)
Ontology gene-sets
Regulation of mitosis
(FDR00.02)
Upregulated ––
Mitosis (FDR00.02) Upregulated AURKA 1.28E-08
PLK1 3.67E-07
SSSCA1 1.56E-07
TPX2 5.53E-06
SMC1A 2.00E-06
Cell cycle phase
(FDR00.02)
Upregulated AURKA 1.28E-08
PLK1 3.67E-07
SSSCA1 1.56E-07
TPX2 5.53E-06
SMC1A 2.00E-06
POLD1 1.22E-06
Mitotic cell cycle
(FDR00.02)
Upregulated AURKA 1.28E-08
SSSCA1 1.56E-07
PLK1 3.67E-07
TPX2 5.53E-06
SMC1A 2.00E-06
POLD1 1.22E-06
Cell cycle process
(FDR00.02)
Upregulated AURKA 1.28E-08
PLK1 3.67E-07
SSSCA1 1.56E-07
TPX2 5.53E-06
SMC1A 2.00E-06
POLD1 1.22E-06
M-phase
(FDR00.02)
Upregulated AURKA 1.28E-08
SSSCA1 1.56E-07
PLK1 3.67E-07
TPX2 5.53E-06
SMC1A 2.00E-06
Collagen
(FDR00.03)
Upregulated LUM 1.22E-06
M-phase of mitotic
cell cycle
(FDR00.03)
Upregulated AURKA 1.28E-08
SSSCA1 1.56E-07
PLK1 3.67E-07
TPX2 5.53E-06
SMC1A 2.00E-06
Chromosomal part
(FDR00.06)
Upregulated RFC3 4.12E-06
SMC1A 2.00E-06
Chromatin binding
(FDR00.06)
Upregulated POLD1 1.22E-06
SUV39H1 4.45E-07
SMC1A 2.00E-06
Chromosome
segregation
(FDR00.07)
Upregulated SMC1A 2.00E-06
Table 5 (continued)
Gene set
(FDR value)
Carcinoma
vs adenoma
Gene
Symbol
P-value
(Wilcoxon
signed
rank test)
Chromosome
pericentric region
(FDR00.07)
Upregulated SMC1A 2.00E-06
Mitotic cell cycle
checkpoint
(FDR00.08)
Upregulated ––
Chromosome
(FDR00.08)
Upregulated SUV39H1 4.45E-07
RFC3 4.12E-06
SMC1A 2.00E-06
Protease inhibitor
activity (FDR00.08)
Upregulated SPP2 1.39E-06
Spindle Upregulated AURKA 1.28E-08
(FDR00.08) TPX2 5.53E-06
Chromatin
(FDR00.08)
Upregulated ––
Microtubule
cytoskeleton
organization and
biogenesis
(FDR00.08)
Upregulated SMC1A 2.00E-06
rRNA metabolic
process
(FDR00.08)
Upregulated ––
Kinetochore
(FDR00.09)
Upregulated ––
rRNA processing
(FDR00.09)
Upregulated ––
Curated gene-sets
Progeria
(FDR00.02)
Upregulated PTGS2 1.67E-06
Old age
(FDR00.09)
Upregulated PLK1 3.67E-07
PTGS2 1.67E-06
Fatty acid
metabolism
(FDR00.09)
Down
regulated
ADH1C 4.12E-06
Positional gene-sets
20q11 (FDR00.09) Upregulated C20ORF24 1.67E-06
TPX2 5.53E-06
20q13 (FDR00.02) Upregulated AURKA 1.28E-08
BMP7 6.46E-08
C20ORF20 9.72E-08
C20ORF11 1.77E-06
BCAS4 1.77E-06
RBM38 2.88E-06
4q22 (FDR00.05) Downregulated ––
aWithin the three differentially expressed processes involved in the
adenoma to carcinoma progression (FDR<0.10), genes that contribute
to the GSEA pathway enrichment score were ranked according to the
difference in mRNA expression between adenomas and CRCs
(Wilcoxon test p-values). Genes with a p-value<1e-5 were considered
significant at the genome-wide level and selected as key genes within
pathways (depicted)
Colorectal Adenoma to Carcinoma Progression 57microtubule-associated, homolog (Xenopus laevis) (TPX2),
polo-like kinase 1(PLK1), Sjogren syndrome/scleroderma
autoantigen 1 (SSSCA1), and Polymerase (DNA directed),
delta 1 (POLD1).
Of the 1,434 curated gene-sets analysed, two gene-sets
(progeria and old age) showed significantly increased expres-
sion in CRCs compared to adenomas and one gene-set (fatty
acid metabolism) showed significantly decreased expression
(FDR < 0.1) (Table 5).
In the progeria and old age pathways, prostaglandin-
endoperoxide synthase 2 (PTGS2 or COX2) was significantly
overexpressedincarcinomasinrelationtoadenomas(p<1.7e-
6) and therefore considered a key gene for these pathways.
PLK1 was a significantly upregulated gene (p<3.7e-7) in the
old age pathway and therefore considered as well as key gene
in this pathway (Table 5). Alcohol dehydrogenase 1 C
(ADH1C) was significantly downregulated in carcinomas in
relationtoadenomas(p<4.1e-6) and therefore consideredasa
key gene for the fatty acid metabolism pathway (Table 5).
Chromosomal instability, reflected in gross chromosomal
copy number and structural changes, plays an important role
in CRC progression. For this reason we also looked at gene-
sets organised by genomic positions. From a total of 257
gene-sets based on genomic positions, those that were dif-
ferentially expressed between adenomas and carcinomas
were selected. Considering a cut-off value of FDR < 0.1,
the gene-sets on 20q13 and 20q11 were significantly upre-
gulated in carcinomas compared to adenomas while the
gene set on 4q22 was significantly downregulated (Table 5).
Key genes (p<1e-5) within the 20q11 gene set are Chromo-
some 20 open reading frame 24 (C20orf24) and TPX2.
AURKA, Bone morphogenetic protein 7 (BMP7), Chromo-
some 20 open reading frame 20 (C20orf20), Chromosome
20 open reading frame 11 (C20orf11), breast carcinoma
amplified sequence 4 (BCAS4) and RNA binding motif
protein 38 (RBM38) are key genes in the 20q13 position set.
In the gene set on position 4q22 no individual key gene was
significantly differentially expressed between carcinomas and
adenomas (Table 5).
4 Discussion
In the present study we compared genome-wide gene ex-
pression in a collection of 37 colorectal adenomas and 31
carcinomas. Previously, this data set has been studied for
20q associated candidate oncogenes as well as for exploring
the involvement of carcinogenic pathways in colorectal
adenoma to carcinoma progression [5, 35]. The present
study aimed to unravel, in an unbiased way, which genes
show altered expression in the progression from adenoma to
carcinoma, and could thus play a role in CRC progression.
In addition, the effect of this altered expression on tumour
biology was evaluated using GSEA pathway analysis with
three different types of predefined gene-sets, i.e. ontology
gene-sets, curated gene-sets, and gene-sets organized by
chromosomal position.
4.1 Differentially expressed genes
mRNA expression was significantly different between ade-
nomas and carcinomas (p<1e-5) for 248 genes, of which 96
were upregulated and 152 downregulated in carcinomas
compared to adenomas. Of these, some have previously
been found to be upregulated in colon cancer, like,
Frizzled-related protein 4 (SFRP4)[ 39], AURKA [40] Bone
morphogenetic protein 7 (BMP7)[ 41] and Centromere pro-
tein H (CENPH)[ 42] or downregulated in cancer like,
prostaglandin E receptor 4 (PTGER4)[ 43] and inhibitor of
DNA binding 4 (ID4)[ 44], supporting the validity of the
arrays and analyses procedures used in the present study.
However, most genes were not been described in previous
expression microarray studies comparing colorectal adeno-
mas to carcinomas [31–34]. This discrepancy could be
explained by the fact that these studies used different plat-
forms (either Affymetrix arrays or cDNA microarrays) and
different strategies for gene selection compared to the pres-
ent study. Nonetheless, 8 of the 248 differentially expressed
genes observed in the present study, including 2 of the top
downregulated genes, are also described to be differentially
expressed through CRC progression by Skrzypczak and
collaborators [34].
The most upregulated genes in carcinomas in comparison
to adenomas were SPON2 and RGS16. SPON2 encodes for
an adhesion molecule present in the extra cellular matrix.
RGS16 encodes for a protein that inhibits signal transduc-
tion by increasing the GTPase activity of G protein alpha
subunits. The most downregulated genes in carcinomas in
comparison to adenomas were FAM55D and PRKACB. Not
much is known about FAM55D while PRKACB is involved in
the regulation of several cellular processes like proliferation,
cell cycle and microtubule dynamics.
Of the top 20 most upregulated genes, 12 have already
been found to be overexpressed in epithelial cancers namely,
colon, prostate or breast cancer, i.e. SPON2 [45], RGS16
[46], SFRP4 [39], AURKA [5, 40] TIE1 [47], CTHRC1 [48],
BMP7 [41], C20orf20 [5, 49], ISG15 [50], CCL21 [51],
TCFL5 [5, 52] and CENPH [42]. Of the top 20 most down-
regulated genes, five have been associated with epithelial
cancer before (including colon cancer), i.e. ENTPD5 [53],
PTGER4 [43], CACNA2D2 [54], ID4 [44] and UGT1A6
[55]. Downregulation of UGT1A6 as well as PRKACB
genes was also observed by others [34]. In addition, ten of
the genes differentially expressed between adenomas and
carcinomas (TPX2, TCFL5, SLC26A10 and CENPH upre-
gulated and SPTBN2, SOCS6, SLITRK6, HR, ETFDH and
58 B. Carvalho et al.APOB48R downregulated) have previously been described
to be mutated in CRC [7]. This overlap with existing data
corroborated the validity of the approach that was used.
Some of these genes have already been quite extensively
studied and in the case of AURKA even used as target for
anticancer therapy. Very recently, in a census of amplified
and overexpressed human cancer genes, AURKA was de-
scribed as one of the genes for which good evidence of
involvement in the development of human cancer was
shown [56]. In CRC in particular, AURKA was shown to
be amplified [11] and overexpressed [40]. We also have
shown that overexpression of AURKA in CRC was correlat-
ed with the copy number increase of 20q13.2 genomic
region and was implicated in the chromosomal instability-
related adenoma to carcinoma progression [5]. AURKA has
a role in centrosome duplication as well as proper chromo-
some alignment and segregation and its abnormal expres-
sion leads to centrosome anomalies and chromosomal
instability [57]. Moreover, overexpression of AURKA indu-
ces malignant transformation [58]. Another well studied
gene is BMP7. It has been associated with e.g. lung, pros-
tate, breast, cervical and colorectal cancer [41, 59–62].
BMP7 can act as suppressor of tumour development by e.g.
inhibiting cellular motility in lung cancer cells [59]o rp r o -
moting growth arrest by repressing telomerase activity in
cervical cancer cells [62]. In colorectal cancer, BMP7 has
been shown to promote invasive potential [41] and to be
associated with liver metastasis and poor prognosis of CRC
patients [63].
The PAM analysis revealed a set of 8 genes (all included
in the 248 differentially expressed genes), which helped the
classifier to achieve best performance. Moreover, when
looking at the performance of differentially expressed genes
in an independent expression data set, we observed that
these genes classified adenomas and carcinomas with an
accuracy of 71%, which was improved to 89%, if using
only the upregulated genes. This result is very promising,
given the fact that upregulated genes are suitable to be used
as biomarkers in a clinical setting.
4.2 Upregulated pathways
Analysis of the differences in gene expression between
adenomas and carcinomas at the level of specific biological
processes showed that ageing (defined by the curated gene-
sets progeria and old age), ontology based gene-sets associ-
ated with chromosomal instability and the chromosomal
position gene-sets 20q11 and 20q13 were upregulated in
colon adenoma to carcinoma progression. Not surprisingly,
several of the differentially expressed genes discussed above
emerged as key genes in differentially expressed pathways.
The notion that cancer is associated with ageing is not
new, as in both conditions DNA damage plays a crucial role
[64]. One of the cellular features associated with ageing is
cellular senescence, a process by which cells enter a state of
permanent cell cycle arrest [65]. DNA alterations associated
with early neoplasia, including mutations in oncogenes like
KRAS can promote senescence and may thus contribute to
the oncogene-induced senescence (OIS) [66, 67]. Genes that
provoke bypass of OIS will drive oncogenic-mediated trans-
formation enhancing tumor progression [68].
Senescence is a potent tumour suppressive mechanism
but it can also contribute to malignant progression, as se-
nescent cells secrete pro-inflammatory cytokines which may
be harmful for the surrounding microenvironment [65, 69].
Interestingly, in the present study one of the key genes in the
activity of both ageing-related gene-sets is PTGS2 (COX-2).
PTGS2 is responsible for the biosynthesis of prostanoids
involved in inflammation and mitogenesis and it is known
to be overexpressed in colorectal cancer [70].
Analysis of the ontology gene-sets revealed that the
genes contributing most to the difference between adenomas
and carcinomas were involved in chromosome binding,
chromosome segregation, mitosis and cell cycle. These
functions are frequently disrupted in chromosomal instable
tumours [71]. Interestingly, these genes overlap with upre-
gulation of key genes within the gene-sets located on 20q
(20q11 and 20q13). This result is consistent with the obser-
vation thatgainof the long arm of chromosome 20isthe most
frequent chromosomal event in colon cancer. Moreover, we
have previously reported on an association between 20q gain
and progression from colorectal adenoma to carcinoma [4, 5].
Within these locations eight key genes were identified, ex-
pression of which contributed most to the difference between
adenomas and carcinomas. Among those, four have previous-
ly been described by us to have a putative role in progression,
namely C20orf24, AURKA, C20orf20 and RBM38 [5]. The
other four were BMP7, TPX2, BCAS4 and C20orf11.
Another gene ontology set that was overexpressed in
carcinomas in comparison to adenomas was the collagen
gene set. This emphasizes the role of the stroma in the
progression from premalignant adenomas to invasive can-
cer, in which the tumor stroma response, which involved
proliferation of fibroblasts, is a key factor. We previously
showed that gain of 8q24 was associated with increased
stroma percentage in CRCs with 20q gain, which is a key
step in adenoma to carcinoma progression [72].
4.3 Downregulated pathways
Fatty acid metabolism (curated set) and the chromosome
position set 4q22 were the only gene-sets that were down-
regulated in carcinomas when compared to adenomas.
The role of fatty acid metabolism in cancer development
is rather complex. On one hand, fatty acid metabolism is
involved in cancer development and cell growth for the
Colorectal Adenoma to Carcinoma Progression 59necessary synthesis of e.g. cell and organelle membranes
[73]. On the other hand, fatty acid metabolism, through beta
oxidation in complex interaction with glucose metabolism
and hypoxia, plays a role in the energy supply for the cancer
cells [74]. These metabolic changes are stimulated or
inhibited by several oncogenes or tumour suppressor genes
respectively. These genes are known to be involved in
proliferative and survival signalling pathways [75].
One of the top genes contributing to the differential
expression of the fatty acid metabolism pathway is the
alcohol dehydrogenase ADH1C, which is also significantly
downregulated in colorectal carcinomas compared to ade-
nomas at the single gene level and therefore considered a
key gene in the activity of this pathway. Alcohol dehydro-
genase produces carcinogenic acetaldehyde through ethanol
oxidation. Polymorphisms in ADH1C have been associated
with CRC risk in combination with alcohol consumption
[76]. The exact role of ADH1C in adenoma to carcinoma
progression, however, is not immediately obvious from
these data.
GSEA analysis revealed the chromosome 4q22 gene-set
as significantly downregulated in colorectal carcinomas
compared to adenomas. However, in the 4q22 gene-set no
key gene (significantly downregulated in carcinomas com-
pared to adenomas) was identified and no 4q22 genes are in
the top 248 list of differentially expressed genes. This indi-
cates that rather subtle changes at the individual gene level
may contribute to the difference observed for the overall set
of genes. Deletions of 4q occur in colorectal carcinomas but
not in adenomas [5, 77] and no significant gene dosage
effects have been identified for genes at this locus, which
could mean that other mechanisms like mutations and/or
epigenetic regulation are involved. Nonetheless, we have
shown that 4q22.1–4q35.2 deletion is associated with a
worse outcome in stage II colon cancer patients [78].
4.4 ‘Vogelgram’ genes
In the present study, no significant differences in mRNA
expression between adenomas and carcinomas were found
for genes traditionally attributed to CRC development like
APC, KRAS, TP53 and DCC [6]. It is not surprising that
initial events like altered expression of APC or KRAS do not
appear in this analysis because expression of these genes is
already altered in many adenomas. On the other hand, to
some extent this may be due to technical reasons. When
base line expression levels of genes are not very high, loss
of expression would result in only a relatively minor signal
that could remain undetected.
In summary, whole genome mRNA expression patterns
of colorectal adenomas and carcinomas were compared and
a set of 248 genes were significantly up or downregulated in
carcinomas compared to adenomas, suggesting a functional
role of these genes in the progression from colorectal ade-
noma to carcinoma. Gene-sets at chromosomes 4q22 and
20q and biological processes like ageing (which is associated
with senescence), chromosomal instability and fatty acid me-
tabolism were differentially expressed in colorectal adenoma
to carcinoma progression.
These data are consistent with the notion that adenomas
and carcinomas are distinct biological entities. Disruption of
specific biological processes like senescence, maintenance
of chromosomal instability and altered metabolism are key
factors in the progression from adenoma to carcinoma.
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